Loading...
•
Sep 30, 2023
scPharmaceuticals Q3 2023 Earnings Report
scPharmaceuticals reported Q3 2023 financial results and provided a business update.
Key Takeaways
scPharmaceuticals generated $3.8 million in net FUROSCIX revenue and ended Q3 2023 with $90.2 million in cash, cash equivalents, and short-term investments. The company also reached an agreement with a large IDN for FUROSCIX access and added 12 sales territories.
Net FUROSCIX revenue was $3.8 million.
Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million.
Reached an agreement with a large IDN providing unrestricted access to FUROSCIX to over 8 million lives.
Added 12 sales territories, bringing the total field force to 66 territories.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals Revenue by Segment
Revenue by Segment
FUROSCIX Revenue
CapyFin.com Forward Guidance
scPharmaceuticals is focused on driving continued uptake of FUROSCIX and advancing life cycle management initiatives, including potential indication expansions and the development of an auto-injector.
Positive Outlook
- Potential expansion of the FUROSCIX indication to include NYHA Class IV heart failure patients.
- Additional indications such as chronic kidney disease.
- Introduction of greater dosing flexibility through the development of an auto-injector.
- Advancing discussions with national and regional payers.
- Positive demand trends reflecting growing awareness of FUROSCIX.
Challenges Ahead
- Unforeseen delays or setbacks in the commercialization of FUROSCIX.
- Risk of the ability of the FUROSCIX On-Body Infusor to appropriately deliver therapy.
- Risks related to manufacturing and quality assurances processes.
- Global economic factors and uncertainties, including as a result of the COVID-19 pandemic, will impact the Company’s operations.
- The company reported a net loss of $15.6 million for the third quarter of 2023.